← All trials
NCT06072781
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Oct 15, 2028
- Completion date
- Feb 9, 2031
- First posted
- Oct 10, 2023
- Last posted
- Dec 26, 2023
- Enrollment
- 270
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Verastem, Inc.Lead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- GOG Foundation, Inc.Collaborator
- GOG Foundation, Inc.Overall official - principal investigator
- Verastem, Inc.Study director
- GOG Foundation, Inc.Official
- Australia New Zealand Gynaecological Oncology GroupCollaborator
- Korean Gynecologic Oncology GroupCollaborator
- European Network for Gynaecological Oncological TrialOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.